No Data
On January 20, LIVZON PHARMA (01513) spent approximately 9.9981 million yuan to repurchase 0.2749 million shares of A-shares.
LIVZON PHARMA (01513) announced that on January 20, 2025, it spent approximately 9.9981 million yuan to repurchase 27.4...
WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.
① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Zhao Yin International: The Class B medical insurance catalog will be implemented within the year, Innovative Drugs will open up domestic payment space.
Zhao Yin International is Bullish on the valuation recovery of the Medical and Pharmaceutical Industry.
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
LIVZON PHARMA (01513.HK) spent 18.2275 million yuan to repurchase 0.5076 million A-shares on January 17.
On January 17, Gelonghui reported that LIVZON PHARMA (01513.HK) issued an announcement stating that on January 17, 2025, it spent 18.2275 million yuan to repurchase 0.5076 million A-shares at a price of 35.32-36.09 yuan per share.
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings Yet
